CONFERENCE ON RETROVIRUSES
AND OPPORTUNISTIC INFECTIONS

March 8–11, 2020

 

Conference Dates and Location: 
March 8–11, 2020 | Boston, Massachusetts
Abstract Number: 
47

POPULATION-LEVEL VIREMIA PREDICTS HIV INCIDENCE ACROSS UNIVERSAL TEST & TREAT STUDIES

Author(s): 

Maya L. Petersen1, Joseph Larmarange2, Kathleen Wirth3, Timothy Skalland4, Helen Ayles5, Moses R. Kamya6, Shahin Lockman3, Collins C. Iwuji7, François Dabis8

1University of California Berkeley, Berkeley, CA, USA,2Paris Descartes University, Paris, France,3Harvard T.H. Chan School of Public Health, Boston, MA, USA,4Fred Hutchinson Cancer Research Center, Seattle, WA, USA,5Zambart, Lusaka, Zambia,6Makerere University College of Health Sciences, Kampala, Uganda,7Africa Health Research Institute, Mtubatuba, South Africa,8L'Université de Bordeaux, Bordeaux, France,9Botswana Harvard AIDS Institute Partnership, Gabarone, Botswana,10University of California San Francisco, San Francisco, CA, USA,11London School of Hygiene & Tropical Medicine, London, UK

Abstract Body: 

Improved understanding of the extent to which increased population-level viral suppression will reduce HIV incidence is needed. Using data from four large Universal Test and Treat Trials, we evaluated the relationship between viremia and incidence and its consistency across epidemic contexts.

We analyzed data from 105 communities in the PopART (21 communities in South Africa and Zambia, ~ 25,000 adults each), BCPP (30 communities in Botswana, ~3,600 adults each), ANRS 12249 TasP (22 communities in South Africa, ~1,300 adults each) and SEARCH (32 communities in Uganda and Kenya, ~5,000 adults each) studies. Communities ranged from rural to urban and varied in the mobility of their populations and their sex ratio (~30% to 50% male). HIV incidence was measured via repeat testing between 2012-2018. Population viremia ­– % of all adults (HIV+ or HIV-) with HIV viremia – was estimated at midpoint of follow-up based on HIV prevalence and non-suppression among HIV+, with adjustment for differences between the measurement cohort and underlying population. Community-level regression, adjusted for study, was used to quantify the association between HIV incidence and viremia and to evaluate cross-study heterogeneity.

HIV prevalence (measured in 257,929 total persons, PopART: 37,006; BCPP: 12,570; TasP: 20,978; SEARCH: 187,375), ranged from 2% to 40% by community. Non-suppression among HIV+ (measured in 39,928 persons, PopART: 6,233; BCPP: 2,318; TasP: 6,617; SEARCH: 16,209) ranged from 3% to 70%. HIV incidence (measured over 345,844 person-years, PopART: 39,702; BCPP: 8,551; TasP: 26,832; SEARCH: 270,759) ranged from 0.03 to 3.4 per 100PY. Population-level viremia was strongly associated with HIV incidence; pooling across studies, HIV incidence decreased by 0.07/100PY (95% CI: 0.05,0.10, p<0.001) for each 1% absolute decrease in viremia. Incidence was significantly associated with viremia in each study; however, both strength of the incidence-viremia relationship (slope) and projected incidence at 0% viremia (intercept) differed (Figure).

Lower population-level HIV viremia was associated with lower HIV incidence in all four Universal Test and Treat Studies, conducted in a wide range of epidemic contexts in sub-Saharan Africa. Differences in external infection rate (due to variation in community size, mobility, and sex ratio) may have contributed to heterogeneity between studies.

Session Number: 
O-04
Session Title: 
COMMUNITY- AND CLINIC-BASED HIV TREATMENT, PREVENTION INTERVENTIONS, AND INSIGHTS
Presenting Author: 
Maya Petersen
Presenter Institution: 
University of California, Berkeley